# Outlook Therapeutics (OTLK) — Analyst Forecast

OTLK · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/otlk/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 2 | 1 | 0 | 3 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $1.60 | $5.37 | $10.50 | 3 |

Last price $0.50 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 11, 2026 | Ascendiant Capital | Maintained | Buy | $10.50 |
| Aug 14, 2026 | BTIG | Maintained | Buy | $4.00 |
| Jul 27, 2026 | BTIG | Upgraded | Neutral → Buy | $4.00 |
| Jul 27, 2026 | HC Wainwright & Co. | Maintained | Neutral | $1.60 |
| Jun 11, 2026 | Ascendiant Capital | Maintained | Buy | $10.00 |
| May 18, 2026 | BTIG | Downgraded | Buy → Neutral | — |
| Mar 11, 2026 | Ascendiant Capital | Maintained | Buy | $6.00 |
| Feb 18, 2026 | Chardan Capital | Maintained | Neutral | $1.00 |
| Feb 18, 2026 | HC Wainwright & Co. | Maintained | Neutral | $0.50 |
| Jan 5, 2026 | Chardan Capital | Maintained | Neutral | $1.00 |
| Jan 2, 2026 | HC Wainwright & Co. | Maintained | Neutral | $0.50 |
| Dec 22, 2025 | Ascendiant Capital | Maintained | Buy | $10.00 |
| Sep 30, 2025 | HC Wainwright & Co. | Maintained | Neutral | $1.00 |
| Sep 22, 2025 | Ascendiant Capital | Maintained | Buy | $8.00 |
| Aug 29, 2025 | HC Wainwright & Co. | Downgraded | Buy → Neutral | $1.00 |
| Aug 29, 2025 | Guggenheim | Downgraded | Buy → Neutral | — |
| Aug 28, 2025 | Chardan Capital | Maintained | Neutral | $3.00 |
| Aug 15, 2025 | Chardan Capital | Maintained | Neutral | $3.00 |
| Jun 6, 2025 | Ascendiant Capital | Maintained | Buy | $21.00 |
| Feb 24, 2025 | Ascendiant Capital | Maintained | Buy | $24.00 |

## Frequently Asked Questions

### What is the price target for OTLK stock?

The average 12-month analyst price target for Outlook Therapeutics (OTLK) is $5.37, with a high estimate of $10.50 and a low of $1.60, across 3 analysts.

### Is OTLK a buy, sell, or hold?

Analysts covering Outlook Therapeutics currently average a Buy rating: 2 buy, 1 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for OTLK?

The average price target of $5.37 implies 973.33% upside from the last price of $0.50.

### What is the latest analyst rating on OTLK?

On Sep 11, 2026, Ascendiant Capital maintained Outlook Therapeutics at Buy with a price target of $10.50.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).